Phaseline

Companies › ONY

ONY: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 3; Respiratory.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Infasurf Aero™ (Calfactant)
Pulmonary surfactant replacement therapy
–Phase 3Respiratory Distress Syndrome (Neonatal)–

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05960929Infasurf Aero™ (Calfactant)Phase 3Respiratory Distress Syndrome (Neonatal)RespiratoryJan 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

SamA Pharmaceutical Aerogen Pharma Lunan Better Pharmaceutical Biotest Areteia Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.